BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Piramal Imaging Highlights New Data for Florbetaben F18 at AAIC 2013


7/12/2013 9:57:22 AM

BERLIN, BOSTON and MUMBAI, India, July 12, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from five studies evaluating the Company's PET amyloid imaging agent (florbetaben F18*) will be presented at the 2013 Alzheimer's Association International Conference® (AAIC 2013) taking place in Boston, Mass. from July 13-18.

(Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO )

"These findings continue to reinforce the strength of the florbetaben F18 development program," said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging SA. "We look forward to sharing the data analysis with our colleagues and the scientific community at AAIC 2013."

Florbetaben is currently being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.

Presentations highlighting florbetaben F18 clinical data include:

  • Midlife Vascular Risk and Late-life Amyloid Burden: Data from the Women's Healthy Ageing Project (WHAP)
    Oral Presentation: Tuesday, July 16, 2013, 4:00 p.m. 5:30 p.m., BCEC Room 258 ABC
  • Atrophy Correction Enhances the Diagnostic Performance of Florbetaben beta-Amyloid PET Imaging
    Poster Session: Saturday, July 13, 2013, 12:30 p.m. 2:30 p.m., BCEC Exhibit Hall A
  • PET Imaging using [18F] Florbetaben PET in Alzheimer's Disease Mouse Models
    Poster Session: Saturday, July 13, 2013, 12:30 p.m. 2:30 p.m., BCEC Exhibit Hall A
  • Multi-center Phase 2 Trial of Florbetaben beta-Amyloid PET Imaging in Alzheimer's Disease Results in a Close to Clinical Routine Situation
    Poster Session: Sunday, July 14, 2013, 11:45 a.m. 2:15 p.m., BCEC Exhibit Hall A
  • 10-Year MRI changes and FBB PET: Results from the Women's Healthy Ageing Project (WHAP)
    Poster Session: Monday, July 15, 2013, 11:45 a.m. 2:15 p.m., BCEC Exhibit Hall A

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

About Piramal Imaging SA
Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases leading to better therapeutic outcomes and improved quality of life. For more information please go to http://imaging.piramalenterprises.com.

About Piramal Enterprises Ltd.
Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over $650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectable anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

*Florbetaben is an investigational PET amyloid imaging agent currently under review by the U.S. Food and Drug Administration and the European Medicines Agency.

For media inquiries, please contact:

Tammy Best

Marketing Communications Manager

Piramal Enterprises Imaging Division

Contact: +1 617-725-0070 x408

tammy.best@piramal.com

Akansha Pradhan

Corporate Communications

Piramal Group

Contact: +91 3351 4082

akansha.pradhan@piramal.com

SOURCE Piramal Imaging



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES